Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Mitsuya Website

Hiroaki Mitsuya, M.D., Ph.D.

Selected Publications

1)  Yedidi RS, Garimella H, Aoki M, Aoki H, Desai DV, Chang SB, Davis DA, Fyvie WS, Kaufman JD, Smith DW, Das D, Wingfield PT, Maeda K, Ghosh AK, Mitsuya H.
Conserved hydrogen-bonding network of P2 bis-tetrahydrofuran containing HIV-1 protease inhibitors (PI) with protease active site amino acid-backbone aid in their activity against PI-resistant HIV.
Antimicrob. Agents Chemother. [Epub ahead of print], 2014.
[Journal]
2)  Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H.
Delayed emergence of HIV-1 variants resistant to 4"-ethynyl-2-fluoro-2"-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Antivir. Ther. (Lond.). 19: 179-89, 2014.
[Journal]
3)  Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H.
EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.
J. Invest. Dermatol. 134: 1158-61, 2014.
[Journal]
4)  Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.
IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Eur. J. Haematol. [Epub ahead of print], 2014.
[Journal]
5)  Muftuoglu Y, Sohl CD, Mislak AC, Mitsuya H, Sarafianos SG, Anderson KS.
Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4"-ethynyl-2-fluoro-2"-deoxyadenosine (EFdA) using pre-steady-state kinetics.
Antiviral Res. 106C: 1-4, 2014.
[Journal]
6)  Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S.
Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial.
Intern. Med. 52: 735-44, 2013.
[Journal]
7)  Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S.
Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
Free Radic. Biol. Med. 65: 778-88, 2013.
[Journal]
8)  Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.
Effects of substitutions at the 4" and 2 positions on the bioactivity of 4"-ethynyl-2-fluoro-2"-deoxyadenosine.
Antimicrob. Agents Chemother. 57: 6254-64, 2013.
[Journal]
9)  Hachiya A, Reeve AB, Marchand B, Michailidis E, Ong YT, Kirby KA, Leslie MD, Oka S, Kodama EN, Rohan LC, Mitsuya H, Parniak MA, Sarafianos SG.
Evaluation of combinations of 4'-ethynyl-2-fluoro-2'-deoxyadenosine with clinically used antiretroviral drugs.
Antimicrob. Agents Chemother. [Epub ahead of print], 2013.
[Journal]
10)  Salcedo Gómez PM, Amano M, Yashchuk S, Mizuno A, Das D, Ghosh AK, Mitsuya H.
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Antimicrob. Agents Chemother. 57: 6110-21, 2013.
[Journal]
11)  Amano M, Tojo Y, Salcedo-Gómez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H.
GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro.
Antimicrob. Agents Chemother. 57: 2036-46, 2013.
[Journal]
12)  Tokunaga K, Yamaguchi S, Iwanaga E, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.
High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.
Eur. J. Haematol. 91: 201-8, 2013.
[Journal]
13)  Ghosh AK, Parham GL, Martyr CD, Nyalapatla PR, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.
Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.
J. Med. Chem. 56: 6792-802, 2013.
[Journal]
14)  Michailidis E, Ryan EM, Hachiya A, Kirby KA, Marchand B, Leslie MD, Huber AD, Ong YT, Jackson JC, Singh K, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
Retrovirology. 10: 65, 2013.
[Journal]
15)  Kawano Y, Kikukawa Y, Fujiwara S, Wada N, Okuno Y, Mitsuya H, Hata H.
Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Int. J. Oncol. 43: 1809-16, 2013.
[Journal]
16)  Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H.
P2" benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
Antimicrob. Agents Chemother. 57: 4920-7, 2013.
[Journal]
17)  Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, Hata H.
PDK1 inhibition is a novel therapeutic target in multiple myeloma.
Br. J. Cancer. 108: 170-8, 2013.
[Journal]
18)  Zhang W, Parniak MA, Mitsuya H, Sarafianos SG, Graebing PW, Rohan LC.
Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention.
Drug Dev Ind Pharm. [Epub ahead of print], 2013.
[Journal]
19)  Yuki H, Ueno S, Tatetsu H, Niiro H, Iino T, Endo S, Kawano Y, Komohara Y, Takeya M, Hata H, Okada S, Watanabe T, Akashi K, Mitsuya H, Okuno Y.
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
Blood. 121: 962-70, 2013.
[Journal]
20)  Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S.
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
PLoS ONE. 8: e73639, 2013.
[Journal]
21)  Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, Larue RC, Patel PA, Mitsuya H, Kessl JJ, Engelman A, Fuchs JR, Kvaratskhelia M.
The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.
J. Biol. Chem. 288: 15813-20, 2013.
[Journal]
22)  Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS.
Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.
Mol. Pharmacol. 82: 125-33, 2012.
[Journal]
23)  Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, Burke DH, Johnson M, Ding S, Zheng YM, Liu SL, Kodama E, Delviks-Frankenberry KA, Pathak VK, Mitsuya H, Parniak MA, Singh K, Sarafianos SG.
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.
Nucleic Acids Res. 40: 345-59, 2012.
[Journal]
24)  Maeda K, Das D, Nakata H, Mitsuya H.
CCR5 inhibitors: emergence, success, and challenges.
Expert Opin Emerg Drugs. 17: 135-45, 2012.
[Journal]
25)  Edwards CK, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H, Kawaguchi T, Sakata KM, Cheronis J, Trollinger D, Bankaitis-Davis D, Dinarello CA, Norris DA, Bevilacqua MP, Fujita M, Burmester GR.
Combined anti-tumor necrosis factor-a therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.
Front Immunol. 3: 366, 2012.
[Journal]
26)  Michailidis E, Singh K, Ryan EM, Hachiya A, Ong YT, Kirby KA, Marchand B, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.
Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.
Cell. Mol. Biol. (Noisy-le-grand). 58: 187-95, 2012.
[Journal]
27)  Ghosh AK, Anderson DD, Weber IT, Mitsuya H.
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
Angew. Chem. Int. Ed. Engl. 51: 1778-802, 2012.
[Journal]
28)  Aoki M, Danish ML, Aoki-Ogata H, Amano M, Ide K, Das D, Koh Y, Mitsuya H.
Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.
J. Virol. 86: 13384-96, 2012.
[Journal]
29)  Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, Anderson KS.
Mechanism of interaction of human mitochondrial DNA polymerase ? with the novel nucleoside reverse transcriptase inhibitor 4"-ethynyl-2-fluoro-2"-deoxyadenosine indicates a low potential for host toxicity.
Antimicrob. Agents Chemother. 56: 1630-4, 2012.
[Journal]
30)  Kawano Y, Fujiwara S, Wada N, Izaki M, Yuki H, Okuno Y, Iyama K, Yamasaki H, Sakai A, Mitsuya H, Hata H.
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Int. J. Oncol. 41: 876-84, 2012.
[Journal]
31)  Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA.
Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4"-ethynyl-2-fluoro-2"-deoxyadenosine in vitro and in vivo.
Antimicrob. Agents Chemother. 56: 4707-12, 2012.
[Journal]
32)  Ghosh AK, Chapsal BD, Steffey M, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.
Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.
Bioorg. Med. Chem. Lett. 22: 2308-11, 2012.
[Journal]
33)  Okuno Y, Tatetsu H, Nosaka K, Mitsuya H.
Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication.
J Clin Exp Hematop. 52: 101-6, 2012.
[Journal]
34)  Kawano Y, Ueno S, Abe M, Kikukawa Y, Yuki H, Iyama K, Okuno Y, Mitsuya H, Hata H.
TRAIL produced from multiple myeloma cells is associated with osteolytic markers.
Oncol. Rep. 27: 39-44, 2012.
[Journal]
35)  Nambu T, Hamada A, Nakashima R, Yuki M, Kawaguchi T, Mitsuya H, Saito H.
Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.
Biol. Pharm. Bull. 34: 114-9, 2011.
[Journal]
36)  Ghosh AK, Chapsal BD, Baldridge A, Steffey MP, Walters DE, Koh Y, Amano M, Mitsuya H.
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
J. Med. Chem. 54: 622-34, 2011.
[Journal]
37)  Ghosh AK, Chapsal BD, Parham GL, Steffey M, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.
Design of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P2-Ligands: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Crystal Structure.
J. Med. Chem. 54: 5890-901, 2011.
[Journal]
38)  Ghosh AK, Martyr CD, Steffey M, Wang YF, Agniswamy J, Amano M, Weber IT, Mitsuya H.
Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands.
ACS Med Chem Lett. 2: 298-302, 2011.
[Journal]
39)  Nishizawa R, Nishiyama T, Hisaichi K, Minamoto C, Murota M, Takaoka Y, Nakai H, Tada H, Sagawa K, Shibayama S, Fukushima D, Maeda K, Mitsuya H.
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Bioorg. Med. Chem. 19: 4028-42, 2011.
[Journal]
40)  Koh Y, Aoki M, Danish ML, Aoki-Ogata H, Amano M, Das D, Shafer RW, Ghosh AK, Mitsuya H.
Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
J. Virol. 85: 10079-89, 2011.
[Journal]
41)  Iwanaga E, Nanri T, Mitsuya H, Asou N.
Mutation in the RNA binding protein TIS11D/ZFP36L2 is associated with the pathogenesis of acute leukemia.
Int. J. Oncol. 38: 25-31, 2011.
[Journal]
42)  Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H.
Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
Antimicrob. Agents Chemother. 55: 1717-27, 2011.
[Journal]
43)  Nishizawa R, Nishiyama T, Hisaichi K, Minamoto C, Matsunaga N, Takaoka Y, Nakai H, Jenkinson S, Kazmierski WM, Tada H, Sagawa K, Shibayama S, Fukushima D, Maeda K, Mitsuya H.
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.
Bioorg. Med. Chem. Lett. 21: 1141-5, 2011.
[Journal]
44)  Kirby KA, Singh K, Michailidis E, Marchand B, Kodama EN, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG.
The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.
Cell. Mol. Biol. (Noisy-le-grand). 57: 40-6, 2011.
[Journal]
45)  Maeda K, Mitsuya H.
Hall J, Hall B, Cockerell C, eds.
Development of antiviral therapeutics for HIV-1 infection and AIDS. In: AIDS in the 21st Century.
Shelton, CT: People's Medical Publishing House USA, Ltd.; 2010. In Press. [Book Chapter]
46)  Ghosh A, Chapsal B, Mitsuya H.
Ghosh A, eds.
Darunavir, a new PI with dual mechanism: from a novel drug design concept to new hope against drug-resistant HIV. In: Aspartic Acid Proteases as Therapeutic Targets.
Weinheim: Wiley-VCH GmbH & Co. KgaA; 2010. In Press. [Book Chapter]
47)  Mitsuya H, Ghosh A.
Ghosh A, eds.
Development of HIV-1 protease inhibitors, antiretroviral resistance and current challenges of HIV/AIDS management. In: Aspartic Acid Proteases as Therapeutic Targets.
Weinheim: Wiley-VCH GmbH & Co. KgaA; 2010. In Press. [Book Chapter]
48)  Nanri T, Uike N, Kawakita T, Iwanaga E, Mitsuya H, Asou N.
A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.
Genes Chromosomes Cancer. 49: 237-41, 2010.
[Journal]
49)  Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, Yonemura Y, Komohara Y, Takeya M, Mitsuya H, Ihn H.
Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.
Arthritis Res. Ther. 12: R128, 2010.
[Journal]
50)  Nakamura M, Kikukawa Y, Takeya M, Mitsuya H, Hata H.
Clarithromycin attenuates autophagy in myeloma cells.
Int. J. Oncol. 37: 815-20, 2010.
[Journal]
51)  Nishizawa R, Nishiyama T, Hisaichi K, Hirai K, Habashita H, Takaoka Y, Tada H, Sagawa K, Shibayama S, Maeda K, Mitsuya H, Nakai H, Fukushima D, Toda M.
Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.
Bioorg. Med. Chem. 18: 5208-23, 2010.
[Journal]
52)  Nakata H, Kruhlak M, Kamata W, Ogata-Aoki H, Li J, Maeda K, Ghosh AK, Mitsuya H.
Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
Antivir. Ther. 15: 321-31, 2010.
[Journal]
53)  Tsuji T, Takatsu N, Nosaka K, Kawakita T, Nanri T, Horikawa K, Mitsuya H, Asou N.
Extramedullary tumors presenting double vision in patients with t(8;21)(q22;q22) acute myeloid leukemia lacking mutations in the receptor tyrosine kinase genes KIT or FLT3.
Leuk. Res. 34: e320-2, 2010.
[Journal]
54)  Koh Y, Amano M, Towata T, Danish M, Leshchenko-Yashchuk S, Das D, Nakayama M, Tojo Y, Ghosh AK, Mitsuya H.
In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.
J. Virol. 84: 11961-9, 2010.
[Journal]
55)  Suzushima H, Wada N, Yamasaki H, Eto K, Shimomura T, Kugimiya MH, Horikawa K, Nishimura S, Tsuda H, Mitsuya H, Asou N.
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.
Leuk. Res. 34: 610-4, 2010.
[Journal]
56)  Tojo Y, Koh Y, Amano M, Aoki M, Das D, Kulkarni S, Anderson DD, Ghosh AK, Mitsuya H.
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Antimicrob. Agents Chemother. 54: 3460-70, 2010.
[Journal]
57)  Ghosh AK, Xu CX, Rao KV, Baldridge A, Agniswamy J, Wang YF, Weber IT, Aoki M, Miguel SG, Amano M, Mitsuya H.
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
ChemMedChem. 5: 1850-4, 2010.
[Journal]
58)  Nishizawa R, Nishiyama T, Hisaichi K, Hirai K, Habashita H, Takaoka Y, Tada H, Sagawa K, Shibayama S, Maeda K, Mitsuya H, Nakai H, Fukushima D, Toda M.
Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles.
Bioorg. Med. Chem. Lett. 20: 763-6, 2010.
[Journal]
59)  Maeda K, Mitsuya H.
Structure-guided molecular-targeting approach for development of AIDS therapeutics.
Nippon Rinsho. 68: 1889-95, 2010.
[Journal]
60)  Yamada R, Horikawa K, Ishihara S, Hoshino K, Kawaguchi T, Iyama K, Mitsuya H, Asou N.
Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug.
Int. J. Hematol. 91: 711-5, 2010.
[Journal]
61)  Yamada Y, Ikuta Y, Nosaka K, Miyanari N, Hayashi N, Mitsuya H, Baba H.
Successful treatment of Cisplatin overdose with plasma exchange.
Case Report Med. 2010: 802312, 2010.
[Journal]
62)  Asou N, Iwanaga E, Nanri T, Mitsuya H.
Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.
Haematologica. 95: e1, 2010.
[Journal]
63)  Kawano Y, Nakama T, Hata H, Kimura E, Maruyoshi N, Uchino M, Mitsuya H.
Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia.
J. Neurol. Sci. 297: 101-4, 2010.
[Journal]
64)  Ghosh AK, Gemma S, Simoni E, Baldridge A, Walters DE, Ide K, Tojo Y, Koh Y, Amano M, Mitsuya H.
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.
Bioorg. Med. Chem. Lett. 20: 1241-6, 2010.
[Journal]
65)  Iwanaga E, Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N.
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.
Haematologica. 94: 433-5, 2009.
[Journal]
66)  Iwanaga E, Nakamura M, Nanri T, Kawakita T, Horikawa K, Mitsuya H, Asou N.
Acute promyelocytic leukemia harboring a STAT5B-RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B-RARA.
Eur. J. Haematol. 83: 499-501, 2009.
[Journal]
67)  Ghosh AK, Leshchenko-Yashchuk S, Anderson DD, Baldridge A, Noetzel M, Miller HB, Tie Y, Wang YF, Koh Y, Weber IT, Mitsuya H.
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
J. Med. Chem. 52: 3902-14, 2009.
[Journal]
68)  Toulza F, Nosaka K, Takiguchi M, Pagliuca T, Mitsuya H, Tanaka Y, Taylor GP, Bangham CR.
FoxP3(+) regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia.
Int. J. Cancer. 125: 2375-82, 2009.
[Journal]
69)  Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H.
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Antimicrob. Agents Chemother. 53: 997-1006, 2009.
[Journal]
70)  Fujiwara S, Miyake H, Nosaka K, Yoshida M, Ishihara S, Horikawa K, Yonemura Y, Iyama K, Mitsuya H, Asou N.
Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia.
Int. J. Hematol. 90: 471-5, 2009.
[Journal]
71)  Nanri T, Iwanaga E, Fujie S, Yamada Y, Horikawa K, Mitsuya H, Asou N.
Micafungin-induced immune hemolysis attacks.
Int. J. Hematol. 89: 139-41, 2009.
[Journal]
72)  Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H.
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
J. Virol. 83: 3059-68, 2009.
[Journal]
73)  Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H.
P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
Biol. Pharm. Bull. 32: 1588-93, 2009.
[Journal]
74)  Hattori S, Ide K, Nakata H, Harada H, Suzu S, Ashida N, Kohgo S, Hayakawa H, Mitsuya H, Okada S.
Potent activity of a Nucleoside Reverse Transcriptase Inhibitor, 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine, against HIV-1 infection in Hu-PBMC-NOD/SCID/JAK3null (NOJ) mouse model.
Antimicrob. Agents Chemother. 53: 3887-93, 2009.
[Journal]
75)  Ueno S, Tatetsu H, Hata H, Iino T, Niiro H, Akashi K, Tenen DG, Mitsuya H, Okuno Y.
PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
Oncogene. 28: 4116-25, 2009.
[Journal]
76)  Kawaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa K, Mitsuya H, Saito H.
Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia.
Int. J. Hematol. 89: 642-8, 2009.
[Journal]
77)  Tatetsu H, Matsuno F, Takatsu N, Miyake H, Hoshino K, Nosaka K, Horikawa K, Hata H, Mitsuya H, Asou N.
Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
Leuk. Res. 33: 197-200, 2009.
[Journal]
78)  Horikawa K, Kudo H, Ishihara S, Miyakawa T, Kawaguchi T, Mitsuya H.
[Aspergillosis of masticator space including mandibular bone responding to itraconazole treatment in a diabetic adult: a case report].
Kansenshogaku Zasshi. 82: 220-3, 2008.
[Journal]
79)  Kawamoto A, Kodama E, Sarafianos SG, Sakagami Y, Kohgo S, Kitano K, Ashida N, Iwai Y, Hayakawa H, Nakata H, Mitsuya H, Arnold E, Matsuoka M.
2'-Deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.
Int. J. Biochem. Cell Biol. 40: 2410-20, 2008.
[Journal]
80)  Yamada Y, Ito K, Watanabe Y, Nosaka K, Horikawa K, Hidaka M, Kawano F, Sasaki Y, Mitsuya H, Asou N.
Allogeneic bone marrow transplantation after l-asparaginase-induced pancreatitis in a patient with acute lymphoblastic leukemia.
Leuk. Res. 32: 1944-6, 2008.
[Journal]
81)  Ghosh AK, Chapsal BD, Baldridge A, Ide K, Koh Y, Mitsuya H.
Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors.
Org. Lett. 10: 5135-8, 2008.
[Journal]
82)  Mitsuya H, Maeda K, Das D, Ghosh AK.
Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.
Adv. Pharmacol. 56: 169-97, 2008.
[Journal]
83)  Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD.
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clin. Cancer Res. 14: 3312-8, 2008.
[Journal]
84)  Ghosh AK, Gemma S, Baldridge A, Wang Y, Kovalevsky AY, Koh Y, Weber IT, Mitsuya H.
Flexible Cyclic Ethers/Polyethers as Novel P2-Ligands for HIV-1 Protease Inhibitors: Design, Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
J. Med. Chem. 51: 6021-33, 2008.
[Journal]
85)  Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S, Kamizaki Y, Mitsuya H, Hata H.
Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid.
Int. J. Oncol. 33: 807-14, 2008.
[Journal]
86)  Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S, Kamizaki Y, Mitsuya H, Hata H.
Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid.
Int. J. Oncol. 33: 807-14, 2008.
[Journal]
87)  Nakamura M, Esumi H, Jin L, Mitsuya H, Hata H.
Induction of necrosis in human myeloma cells by kigamicin.
Anticancer Res. 28: 37-43, 2008.
[Journal]
88)  Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, Norman RB, Hackney LA, Takaoka Y, Mitsuya H.
Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition.
J. Mol. Biol. 381: 956-74, 2008.
[Journal]
89)  Ghosh AK, Gemma S, Takayama J, Baldridge A, Leshchenko-Yashchuk S, Miller HB, Wang YF, Kovalevsky AY, Koh Y, Weber IT, Mitsuya H.
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
Org. Biomol. Chem. 6: 3703-13, 2008.
[Journal]
90)  Nakata H, Steinberg SM, Koh Y, Maeda K, Takaoka Y, Tamamura H, Fujii N, Mitsuya H.
Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
Antimicrob. Agents Chemother. 52: 2111-9, 2008.
[Journal]
91)  Ohrui H, Kohgo S, Hayakawa H, Kodama E, Matsuoka M, Nakata T, Mitsuya H.
2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma.
Nucleosides Nucleotides Nucleic Acids. 26: 1543-6, 2007.
[Journal]
92)  Amano M, Koh Y, Das D, Li J, Leschenko S, Wang YF, Boross PI, Weber IT, Ghosh AK, Mitsuya H.
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Antimicrob. Agents Chemother. 51: 2143-55, 2007.
[Journal]
93)  Nakata H, Amano M, Koh Y, Kodama E, Yang G, Bailey CM, Kohgo S, Hayakawa H, Matsuoka M, Anderson KS, Cheng YC, Mitsuya H.
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Antimicrob. Agents Chemother. 51: 2701-8, 2007.
[Journal]
94)  Murakami YI, Yatabe Y, Sakaguchi T, Sasaki E, Yamashita Y, Morito N, Yoh K, Fujioka Y, Matsuno F, Hata H, Mitsuya H, Imagawa S, Suzuki A, Esumi H, Sakai M, Takahashi S, Mori N.
c-Maf expression in angioimmunoblastic T-cell lymphoma.
Am. J. Surg. Pathol. 31: 1695-702, 2007.
[Journal]
95)  Asou N, Yanagida M, Huang L, Yamamoto M, Shigesada K, Mitsuya H, Ito Y, Osato M.
Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia.
Blood. 109: 4023-7, 2007.
[Journal]
96)  Ghosh AK, Dawson ZL, Mitsuya H.
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Bioorg. Med. Chem. 15: 7576-80, 2007.
[Journal]
97)  Ghosh AK, Chapsal BD, Weber IT, Mitsuya H.
Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance.
Acc Chem Res. 2007.
[Journal]
98)  Maeda K, Mitsuya H.
Development of therapeutics for AIDS: structure-based molecular targeting.
Tuberculosis (Edinburgh, Scotland). 87 Suppl 1: S31-4, 2007.
[Journal]
99)  Tatetsu H, Ueno S, Hata H, Yamada Y, Takeya M, Mitsuya H, Tenen DG, Okuno Y.
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
Cancer Res. 67: 5328-36, 2007.
[Journal]
100)  Harada S, Hazra R, Tamiya S, Zeichner SL, Mitsuya H.
Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy.
Antiviral Res. 75: 159-66, 2007.
[Journal]
101)  Asou N, Izuno Y, Okubo T, Ide K, Ueno H, Kawakita M, Mitsuya H, Hata H.
Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
Int. J. Hematol. 86: 69-71, 2007.
[Journal]
102)  Mitchell MS, Bodine ET, Hill S, Princler G, Lloyd P, Mitsuya H, Matsuoka M, Derse D.
Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.
J. Virol. 81: 4422-8, 2007.
[Journal]
103)  Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H.
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
J Biol Chem. 2007.
[Journal]
104)  Nishizawa R, Nishiyama T, Hisaichi K, Matsunaga N, Minamoto C, Habashita H, Takaoka Y, Toda M, Shibayama S, Tada H, Sagawa K, Fukushima D, Maeda K, Mitsuya H.
Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
Bioorg. Med. Chem. Lett. 17: 727-31, 2007.
[Journal]
105)  Hata H, Mitsuya H.
[Management of bone lesions in multiple myeloma].
Gan To Kagaku Ryoho. 33: 1072-6, 2006.
[Journal]
106)  Mitsuya H.
[Progress in AIDS therapy].
Nippon Naika Gakkai Zasshi. 95: 1845-50, 2006.
[Journal]
107)  Ohrui H, Kohgo S, Hayakawa H, Kodama E, Matsuoka M, Nakata T, Mitsuya H.
2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma.
Nucleic Acids Symp Ser (Oxf). 1-2, 2006.
[Journal]
108)  Zhou S, Kern ER, Gullen E, Cheng YC, Drach JC, Tamiya S, Mitsuya H, Zemlicka J.
9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1.
J. Med. Chem. 49: 6120-8, 2006.
[Journal]
109)  Nakamura M, Gotoh T, Okuno Y, Tatetsu H, Sonoki T, Uneda S, Mori M, Mitsuya H, Hata H.
Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells.
Leuk. Lymphoma. 47: 531-9, 2006.
[Journal]
110)  Gatanaga H, Das D, Suzuki Y, Yeh DD, Hussain KA, Ghosh AK, Mitsuya H.
Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.
J. Biol. Chem. 281: 1241-50, 2006.
[Journal]
111)  Ghosh AK, Ramu Sridhar P, Kumaragurubaran N, Koh Y, Weber IT, Mitsuya H.
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.
ChemMedChem. 1: 939-50, 2006.
[Journal]
112)  Miyazato P, Yasunaga J, Taniguchi Y, Koyanagi Y, Mitsuya H, Matsuoka M.
De Novo Human T-Cell Leukemia Virus Type 1 Infection of Human Lymphocytes in NOD-SCID, Common {gamma}-Chain Knockout Mice.
J. Virol. 80: 10683-91, 2006.
[Journal]
113)  Ghosh AK, Schiltz G, Perali RS, Leshchenko S, Kay S, Walters DE, Koh Y, Maeda K, Mitsuya H.
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
Bioorg. Med. Chem. Lett. 16: 1869-73, 2006.
[Journal]
114)  Habashita H, Kokubo M, Hamano S, Hamanaka N, Toda M, Shibayama S, Tada H, Sagawa K, Fukushima D, Maeda K, Mitsuya H.
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
J. Med. Chem. 49: 4140-52, 2006.
[Journal]
115)  Depboylu C, Eiden LE, Schäfer MK, Reinhart TA, Mitsuya H, Schall TJ, Weihe E.
Fractalkine expression in the rhesus monkey brain during lentivirus infection and its control by 6-chloro-2',3'-dideoxyguanosine.
J. Neuropathol. Exp. Neurol. 65: 1170-80, 2006.
[Journal]
116)  Hanaoka N, Kawaguchi T, Horikawa K, Nagakura S, Mitsuya H, Nakakuma H.
Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP.
Blood. 107: 1184-91, 2006.
[Journal]
117)  Yamada Y, Nishimoto E, Mitsuya H, Yonemura Y.
In vitro transdifferentiation of adult bone marrow Sca-1+ cKit- cells cocultured with fetal liver cells into hepatic-like cells without fusion.
Exp. Hematol. 34: 97-106, 2006.
[Journal]
118)  Davis DA, Brown CA, Singer KE, Wang V, Kaufman J, Stahl SJ, Wingfield P, Maeda K, Harada S, Yoshimura K, Kosalaraksa P, Mitsuya H, Yarchoan R.
Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Antiviral Res. 72: 89-99, 2006.
Full Text Article. [Journal]
119)  Yin PD, Das D, Mitsuya H.
Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance.
Cell Mol Life Sci. 63: 1706-24, 2006.
Full Text Article. [Journal]
120)  Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, Yamada A, Maeda A, Matsuno F, Hata H, Suzuki A, Imagawa S, Mitsuya H, Esumi H, Koyama A, Yamamoto M, Mori N, Takahashi S.
Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human.
Cancer Res. 66: 812-9, 2006.
[Journal]
121)  Kuwata K, Yamada S, Kinuwaki E, Naito M, Mitsuya H.
Peripheral hemophagocytosis: An early indicator of advanced systemic inflammatory response syndrome/hemophagocytic syndrome.
Shock. 25: 344-50, 2006.
[Journal]
122)  Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S.
Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
AIDS. 20: 2065-2073, 2006.
[Journal]
123)  Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, Arnold E, Mitsuya H.
Structural and molecular interactions of CCR5 inhibitors with CCR5.
J. Biol. Chem. 281: 12688-98, 2006.
[Journal]
124)  Ghosh AK, Sridhar PR, Leshchenko S, Hussain AK, Li J, Kovalevsky AY, Walters DE, Wedekind JE, Grum-Tokars V, Das D, Koh Y, Maeda K, Gatanaga H, Weber IT, Mitsuya H.
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
J. Med. Chem. 49: 5252-61, 2006.
[Journal]
125)  Tatetsu H, Asou N, Nakamura M, Hanaoka N, Matsuno F, Horikawa K, Mitsuya H.
Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia.
Am. J. Hematol. 81: 366-9, 2006.
[Journal]
126)  Matsuno N, Nanri T, Kawakita T, Mitsuya H, Asou N.
A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia.
Leukemia. 19: 480-1, 2005.
[Journal]
127)  Tatetsu H, Okuno Y, Nakamura M, Matsuno F, Sonoki T, Taniguchi I, Uneda S, Umezawa K, Mitsuya H, Hata H.
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Mol. Cancer Ther. 4: 1114-20, 2005.
[Journal]
128)  Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N.
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.
Leukemia. 19: 1673-5, 2005.
[Journal]
129)  Depboylu C, Schäfer MK, Schwaeble WJ, Reinhart TA, Maeda H, Mitsuya H, Damadzic R, Rausch DM, Eiden LE, Weihe E.
Increase of C1q biosynthesis in brain microglia and macrophages during lentivirus infection in the rhesus macaque is sensitive to antiretroviral treatment with 6-chloro-2',3'-dideoxyguanosine.
Neurobiol. Dis. 20: 12-26, 2005.
[Journal]
130)  Sonoki T, Iwanaga E, Mitsuya H, Asou N.
Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia.
Leukemia. 19: 2009-10, 2005.
[Journal]
131)  Yonemura Y, Miyake H, Asou N, Mitsuya H.
Long-term efficacy of pegylated recombinant human megakaryocyte growth and development factor in therapy of aplastic anemia.
Int. J. Hematol. 82: 307-9, 2005.
[Journal]
132)  Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H, Asou N.
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
Leukemia. 19: 1361-6, 2005.
[Journal]
133)  Sonoki T, Iwanaga E, Mitsuya H, Asou N.
Ovarian relapse seven years after bone marrow transplantation for B-cell acute lymphoblastic leukemia: an unusual Krukenberg tumor.
Am. J. Hematol. 80: 75-6, 2005.
[Journal]
134)  Matsuno N, Hoshino K, Nanri T, Kawakita T, Suzushima H, Kawano F, Mitsuya H, Asou N.
p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia.
Leuk Res. 29: 557-64, 2005.
[Journal]
135)  Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H.
Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
J Virol. 79: 2087-96, 2005.
[Journal]
136)  Matsushita S, Yoshimura K, Kimura T, Kamihira A, Takano M, Eto K, Shirasaka T, Mitsuya H, Oka S.
Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir containing regimen.
J Clin Virol. 33: 188-93, 2005.
[Journal]
137)  Ghosh AK, Swanson LM, Cho H, Leshchenko S, Hussain KA, Kay S, Walters DE, Koh Y, Mitsuya H.
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
J Med Chem. 48: 3576-85, 2005.
[Journal]
138)  Zhou S, Kern ER, Gullen E, Cheng YC, Drach JC, Matsumi S, Mitsuya H, Zemlicka J.
(Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity.
J Med Chem. 47: 6964-72, 2004.
[Journal]
139)  Siddiqui MA, Hughes SH, Boyer PL, Mitsuya H, Van QN, George C, Sarafinanos SG, Marquez VE.
A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides.
J Med Chem. 47: 5041-8, 2004.
[Journal]
140)  Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mistuya H.
Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.
J Virol. 78: 12030-40, 2004.
[Journal]
141)  Kitano K, Kohgo S, Yamada K, Sakata S, Ashida N, Hayakawa H, Nameki D, Kodama E, Matsuoka M, Mitsuya H, Ohrui H.
Attempt to reduce cytotoxicity by synthesizing the L-enantiomer of 4'-C-ethynyl-2'-deoxypurine nucleosides as antiviral agents against HIV and HBV.
Antivir Chem Chemother. 15: 161-7, 2004.
[Journal]
142)  Depboylu C, Reinhart TA, Takikawa O, Imai Y, Maeda H, Mitsuya H, Rausch D, Eiden LE, Weihe E.
Brain virus burden and indoleamine-2,3-dioxygenase expression during lentiviral infection of rhesus monkey are concomitantly lowered by 6-chloro-2',3'-dideoxyguanosine.
Eur J Neurosci. 19: 2997-3005, 2004.
[Journal]
143)  Kohgo S, Yamada K, Kitano K, Iwai Y, Sakata S, Ashida N, Hayakawa H, Nameki D, Kodama E, Matsuoka M, Mitsuya H, Ohrui H.
Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides.
Nucleosides Nucleotides Nucleic Acids. 23: 671-90, 2004.
[Journal]
144)  Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, Mitsuya H, Matsuoka M.
Identification of aberrantly methylated genes in association with adult T-cell leukemia.
Cancer Res. 64: 6002-9, 2004.
[Journal]
145)  Hachiya A, Gatanaga H, Kodama E, Ikeuchi M, Matsuoka M, Harada S, Mitsuya H, Kimura S, Oka S.
Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naive patients.
Virology. 327: 215-24, 2004.
[Journal]
146)  Hayakawa H, Kohgo S, Kitano K, Ashida N, Kodama E, Mitsuya H, Ohrui H.
Potential of 4'-C-substituted nucleosides for the treatment of HIV-1.
Antivir Chem Chemother. 15: 169-87, 2004.
[Journal]
147)  Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
J Virol. 78: 8654-62, 2004.
[Journal]
148)  Maeda K, Nakata H, Ogata H, Koh Y, Miyakawa T, Mitsuya H.
The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.
Curr Opin Pharmacol. 4: 447-52, 2004.
[Journal]
149)  Matsuno N, Hoshino K, Nanri T, Kawakita T, Mitsuya H, Asou N.
Transcriptional repression of the p15 gene predicts the clinical outcome of acute myeloblastic leukemia with intermediate and adverse cytogenetics.
Leukemia. 18: 1146-8, 2004.
[Journal]
150)  Tatetsu H, Asou N, Nakamura M, Koh Y, Tajiri T, Matsuno F, Horikawa K, Yonemura Y, Mitsuya H.
[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine].
Rinsho Ketsueki. 44: 471-3, 2003.
[Journal]
151)  Choi Y, George C, Comin MJ, Barchi JJ, Kim HS, Jacobson KA, Balzarini J, Mitsuya H, Boyer PL, Hughes SH, Marquez VE.
A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.
J. Med. Chem. 46: 3292-9, 2003.
[Journal]
152)  Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, Mitsuya H, Kawano F, Masaki Y, Sasaki T, Chou T, Yokozawa T, Tobinai K.
A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Jpn. J. Clin. Oncol. 33: 78-85, 2003.
[Journal]
153)  Uneda S, Hata H, Matsuno F, Nagasaki A, Harada N, Mitsuya Y, Matsuzaki H, Mitsuya H.
A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model.
Br. J. Haematol. 120: 396-404, 2003.
[Journal]
154)  Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A.
Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells.
J. Immunol. 170: 4260-6, 2003.
[Journal]
155)  Matsuno N, Osato M, Yamashita N, Yanagida M, Nanri T, Fukushima T, Motoji T, Kusumoto S, Towatari M, Suzuki R, Naoe T, Nishii K, Shigesada K, Ohno R, Mitsuya H, Ito Y, Asou N.
Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
Leukemia. 17: 2492-9, 2003.
[Journal]
156)  Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH.
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Blood. 101: 4653-9, 2003.
[Journal]
157)  Wang R, Harada S, Mitsuya H, Zemlicka J.
Inhibition of human immunodeficiency virus reverse transcriptase by synadenol triphosphate and its E-isomer.
J. Med. Chem. 46: 4799-802, 2003.
[Journal]
158)  Uneda S, Hata H, Matsuno F, Harada N, Mitsuya Y, Kawano F, Mitsuya H.
Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.
Br. J. Haematol. 120: 53-5, 2003.
[Journal]
159)  Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Louis JM, Harrison RW, Weber IT, Ghosh AK, Mitsuya H.
Novel bis-tetrahydrofuranyl urethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) potent against multi-PI-resistant human immunodeficiency virus in vitro.
Antimicrob. Agents Chemother. 47: 3123-3129., 2003.
[Journal]
160)  Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H.
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Antimicrob. Agents Chemother. 47: 3123-9, 2003.
[Journal]
161)  Matsumi S, Kosalaraksa P, Tsang H, Kavlick MF, Harada S, Mitsuya H.
Pathways for the emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants.
AIDS. 17: 1127-1137, 2003.
[Journal]
162)  Tamamura H, Koh Y, Ueda S, Sasaki Y, Yamasaki T, Aoki M, Maeda K, Watai Y, Arikuni H, Otaka A, Mitsuya H, Fujii N.
Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
J. Med. Chem. 46: 1764-8, 2003.
[Journal]
163)  Chen X, Matsumi S, Mitsuya H, Zemlickal J.
Synthesis of (Z)-(2,3-bis-hydroxymethyl)methylenecyclopropane analogues of purine nucleosides.
Nucleosides Nucleotides Nucleic Acids. 22: 265-74, 2003.
[Journal]
164)  Kohgo S, Yamada K, Kitano K, Sakata S, Hayakawa H, Nameki D, Kodama E, Matsuoka M, Mitsuya H, Ohrui H.
Synthesis of 4'-C-ethynyl and 4'-C-cyano purine nucleosides from natural nucleosides and their anti-HIV activity.
Nucleosides Nucleotides Nucleic Acids. 22: 887-9, 2003.
[Journal]
165)  Yoshimura K, Ido E, Akiyama H, Kimura T, Aoki M, Suzuki H, Mitsuya H, Hayami M, Matsushita S.
The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV 89.6P.
J. Virol. Methods. 112: 121-8, 2003.
[Journal]
166)  Hayakawa T, Mitsuya H, Kojima M, Hayase Y.
[The clinical evaluation of 414 cases of male urethritis].
Nippon Hinyokika Gakkai Zasshi. 93: 450-6, 2002.
[Journal]
167)  Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, Ghosh AK, Gulnik SV, Erickson JW, Mitsuya H.
A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.
J. Virol. 76: 1349-58, 2002.
[Journal]
168)  Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Nagashima K, Gorelick RJ, Mardy S, Tang C, Summers MF, Mitsuya H.
Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
J. Biol. Chem. 277: 5952-61, 2002.
[Journal]
169)  Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Mardy S, Gorelick RJ, Tang C, Summers MF, Mitsuya H.
Amino acid substitutions in non-cleavage sites of the gag region are indispensable for high level HIV-1 resistance to protease inhibitors.
J. Biol. Chem. 277: 5952 5961, 2002.
[Journal]
170)  Kudo H, Matsuoka T, Mitsuya H, Nishimura Y, Matsushita S.
Cross-linking HLA-DR molecules on Th1 cells induces anergy in association with increased level of cyclin-dependent kinase inhibitor p27(Kip1).
Immunol. Lett. 81: 149-55, 2002.
[Journal]
171)  Nagakura S, Ishihara S, Dunn DE, Nishimura J, Kawaguchi T, Horikawa K, Hidaka M, Kagimoto T, Eto N, Mitsuya H, Kinoshita T, Young NS, Nakakuma H.
Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro.
Blood. 100: 1031-7, 2002.
[Journal]
172)  Horikawa K, Kawaguchi T, Ishihara S, Nagakura S, Hidaka M, Kagimoto T, Mitsuya H, Nakakuma H.
Frequent detection of T cells with mutations of the hypoxanthine-guanine phosphoribosyl transferase gene in patients with paroxysmal nocturnal hemoglobinuria.
Blood. 99: 24-9, 2002.
[Journal]
173)  Iga M, Okayama A, Stuver S, Matsuoka M, Mueller N, Aoki M, Mitsuya H, Tachibana N, Tsubouchi H.
Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses.
J. Infect. Dis. 185: 691-5, 2002.
[Journal]
174)  Miyakawa T, Obaru K, Maeda K, Harada S, Mitsuya H.
Identification of amino acid residues critical for LD78b (a variant of human macrophage inflammatory protein-1a) binding to CCR5 and inhibition of R5 HIV-1 replication.
J. Biol. Chem. 277: 4649-4655, 2002.
[Journal]
175)  Miyakawa T, Obaru K, Maeda K, Harada S, Mitsuya H.
Identification of amino acid residues critical for LD78beta, a variant of human macrophage inflammatory protein-1alpha, binding to CCR5 and inhibition of R5 human immunodeficiency virus type 1 replication.
J. Biol. Chem. 277: 4649-55, 2002.
[Journal]
176)  Egron D, Périgaud C, Gosselin G, Aubertin AM, Gatanaga H, Mitsuya H, Zemlicka J, Imbach JL.
Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.
Bioorg. Med. Chem. Lett. 12: 265-6, 2002.
[Journal]
177)  Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M.
Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells.
Blood. 99: 634-40, 2002.
[Journal]
178)  Hoshino K, Asou N, Okubo T, Suzushima H, Kiyokawa T, Kawano F, Mitsuya H.
The absence of the p15INK4B gene alterations in adult patients with precursor B-cell acute lymphoblastic leukaemia is a favourable prognostic factor.
Br. J. Haematol. 117: 531-40, 2002.
[Journal]
179)  Wang R, Corbett TH, Cheng YC, Drach JC, Kern ER, Mitsuya H, Zemlicka J.
Tryptophanyl phosphoramidates as prodrugs of synadenol and its E-isomer: synthesis and biological activity.
Bioorg. Med. Chem. Lett. 12: 2467-70, 2002.
[Journal]
180)  Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, Ghosh AK, Erickson J, Mitsuya H.
UIC-94003: a potent protease inhibitor (PI) that inhibits multi-PI-resistant HIV-1 replication in vitro.
J. Virology. 76: 1349-1358, 2002.
[Journal]
181)  Ohrui H, Mitsuya H.
4'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants.
Current drug targets. Infectious disorders. 1: 1-10, 2001.
[Journal]
182)  Kodama EI, Kohgo S, Kitano K, Machida H, Gatanaga H, Shigeta S, Matsuoka M, Ohrui H, Mitsuya H.
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
Antimicrob. Agents Chemother. 45: 1539-46, 2001.
[Journal]
183)  Suzuki Y, Rahman M, Mitsuya H.
Diverse transcriptional response of CD4(+) T cells to stromal cell-derived factor (SDF)-1: cell survival promotion and priming effects of SDF-1 on CD4(+) T cells.
J. Immunol. 167: 3064-73, 2001.
[Journal]
184)  Sakai T, Nosaka K, Tamiya S, Koga S, Mita S, Uchino M, Mitsuya H, Matsuoka M.
Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state.
Blood. 97: 3177-83, 2001.
[Journal]
185)  Richman DD, Johnson VA, Mayers DM, Shirasaka T, O'Brien MC, Mitsuya H.
In vitro evaluation of experimental agents for anti-HIV activity.
Current protocols in immunology / edited by John E. Coligan ... [et al.]. Chapter 12: Unit 12.9, 2001.
[Journal]
186)  Sakai T, Matsuoka M, Aoki M, Nosaka K, Mitsuya H.
Missense mutation of interleukin 12 receptor b1 chain-encoding gene is associated with impaired immunity against mycobacterium avium complex infection.
Blood. 97: 2688-2694, 2001.
[Journal]
187)  Sakai T, Matsuoka M, Aoki M, Nosaka K, Mitsuya H.
Missense mutation of the interleukin-12 receptor beta1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection.
Blood. 97: 2688-94, 2001.
[Journal]
188)  Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K, Miyakawa T, Aoki M, Fukushima D, Mitsuya H.
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
J. Biol. Chem. 276: 35194-35200, 2001.
[Journal]
189)  Kohgo S, Mitsuya H, Ohrui H.
Synthesis of the L-enantiomer of 4'-C-ethynyl-2'-deoxycytidine.
Biosci. Biotechnol. Biochem. 65: 1879-82, 2001.
[Journal]
190)  Ishihara S, Horikawa K, Kawaguchi T, Ke L, Hidaka M, Nagakura S, Mitsuya H, Sendo F, Nakakuma H.
3H9, a monoclonal antibody capable of discriminating neutrophilic from basophilic and eosinophilic granulocytes.
Eur. J. Haematol. 64: 275-6, 2000.
[Journal]
191)  Kawaguchi T, Koga S, Hongo H, Komiyama Y, Li K, Ishihara S, Horikawa K, Hidaka M, Mitsuya H, Nakakuma H.
A novel type of factor XI deficiency showing compound genetic abnormalities: a nonsense mutation and an impaired transcription.
Int. J. Hematol. 71: 84-9, 2000.
[Journal]
192)  Ito H, Matsushita S, Tokano Y, Nishimura H, Tanaka Y, Fujisao S, Mitsuya H, Hashimoto H, Nishimura Y.
Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity.
Hum. Immunol. 61: 366-77, 2000.
[Journal]
193)  Kodama EN, McCaffrey RP, Yusa K, Mitsuya H.
Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells.
Biochem. Pharmacol. 59: 273-81, 2000.
[Journal]
194)  Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H.
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
Clin. Infect. Dis. 30: 313-8, 2000.
[Journal]
195)  Shah FS, Curr KA, Hamburgh ME, Parniak M, Mitsuya H, Arnez JG, Prasad VR.
Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase.
J. Biol. Chem. 275: 27037-44, 2000.
[Journal]
196)  Harada N, Nagasaki A, Hata H, Matsuzaki H, Matsuno F, Mitsuya H.
Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Acta Haematol. 103: 144-51, 2000.
[Journal]
197)  Sei S, Yang QE, O'Neill D, Yoshimura K, Nagashima K, Mitsuya H.
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
J. Virol. 74: 4621-33, 2000.
[Journal]
198)  Nosaka K, Maeda M, Tamiya S, Sakai T, Mitsuya H, Matsuoka M.
Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia.
Cancer Res. 60: 1043-8, 2000.
[Journal]
199)  Mu L, Sarafianos SG, Nicklaus MC, Russ P, Siddiqui MA, Ford H, Mitsuya H, Le R, Kodama E, Meier C, Knispel T, Anderson L, Barchi JJ, Marquez VE.
Interactions of conformationally biased north and south 2'-fluoro-2', 3'-dideoxynucleoside 5'-triphosphates with the active site of HIV-1 reverse transcriptase.
Biochemistry. 39: 11205-15, 2000.
[Journal]
200)  Asou N, Suzushima H, Nishimura S, Okubo T, Yamasaki H, Osato M, Hoshino K, Takatsuki K, Mitsuya H.
Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide.
Am. J. Hematol. 63: 35-7, 2000.
[Journal]
201)  Kudo H, Senju S, Mitsuya H, Nishimura Y.
Mouse and human GTPBP2, newly identified members of the GP-1 family of GTPase.
Biochem. Biophys. Res. Commun. 272: 456-65, 2000.
[Journal]
202)  Pilon AA, Marchand C, Kavlick MF, Bajaj K, Owen J, Mitsuya H, Pommier Y.
Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine.
AIDS Res. Hum. Retroviruses. 16: 1417-22, 2000.
[Journal]
203)  Gao WY, Johns DG, Mitsuya H.
Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine.
Nucleosides Nucleotides Nucleic Acids. 19: 371-7, 2000.
[Journal]
204)  Li K, Kawaguchi T, Ishihara S, Horikawa K, Hidaka M, Sakaguchi M, Tsuruzaki R, Kawakita M, Kagimoto T, Mitsuya H, Nakakuma H.
Rarity of microsatellite alterations in patients with paroxysmal nocturnal haemoglobinuria.
Eur. J. Haematol. 64: 430-2, 2000.
[Journal]
205)  Ohrui H, Kohgo S, Kitano K, Sakata S, Kodama E, Yoshimura K, Matsuoka M, Shigeta S, Mitsuya H.
Syntheses of 4'-C-ethynyl-beta-D-arabino- and 4'-C-ethynyl-2'-deoxy-beta-D-ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity.
J. Med. Chem. 43: 4516-25, 2000.
[Journal]
206)  Kitano K, Sakata S, Kohgo S, Matsuoka M, Kodama E, Mitsuya H, Ohrui H.
Synthesis of 4'-ethynyl-purine nucleosides possessing anti-HIV activity.
Nucleic Acids Symp. Ser. 105-6, 2000.
[Journal]
207)  Shimomura T, Yonemura Y, Miyazoe T, Miyake H, Kato T, Miyazaki H, Mitsuya H, Kawakita M.
Thrombopoietin stimulates murine lineage negative, Sca-1+, C-Kit+, CD34- cells: comparative study with stem cell factor or interleukin-3.
Int. J. Hematol. 71: 33-9, 2000.
[Journal]
208)  Ishihara S, Nakakuma H, Kawaguchi T, Nagakura S, Horikawa K, Hidaka M, Asou N, Mitsuya H.
Two cases showing clonal progression with full evolution from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome to myelodysplastic syndromes and leukemia.
Int. J. Hematol. 72: 206-9, 2000.
[Journal]
209)  Humphrey RW, Wyvill KM, Nguyen BY, Shay LE, Kohler DR, Steinberg SM, Ueno T, Fukasawa T, Shintani M, Hayashi H, Mitsuya H, Yarchoan R.
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Antiviral Res. 41: 21-33, 1999.
[Journal]
210)  Sonoki T, Matsuzaki H, Satterwhite E, Nakazawa N, Hata H, Tucker PW, Taniwaki M, Kuribayashi N, Harada N, Matsuno F, Mitsuya H.
A plasma cell leukemia patient showing bialleic 14q translocations: t(2;14) and t(11;14).
Acta Haematol. 101: 197-201, 1999.
[Journal]
211)  Harada N, Hata H, Matsuno F, Sonoki T, Kuribayashi N, Matsuzaki H, Mitsuya H.
Absence of Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow cells from Japanese myeloma patients.
Leukemia. 13: 1465-6, 1999.
[Journal]
212)  Fujiwara M, Kodama EN, Okamoto M, Tokuhisa K, Ide T, Hanasaki Y, Katsuura K, Takayama H, Aimi N, Mitsuya H, Shigeta S, Konno K, Yokota T, Baba M.
Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217.
Antivir. Chem. Chemother. 10: 315-20, 1999.
[Journal]
213)  Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S.
Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals.
Blood. 93: 1838-42, 1999.
[Journal]
214)  Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H.
Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.
J. Virol. 73: 5356-63, 1999.
[Journal]
215)  Davis DA, Yusa K, Gillim LA, Newcomb FM, Mitsuya H, Yarchoan R.
Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.
J. Virol. 73: 1156-64, 1999.
[Journal]
216)  Sonoki T, Matsuzaki H, Nagasaki A, Hata H, Yoshida M, Matsuoka M, Kuribayashi N, Kimura T, Harada N, Takatsuki K, Mitsuya H, Mori M.
Detection of inducible nitric oxide synthase (iNOS) mRNA by RT-PCR in ATL patients and HTLV-I infected cell lines: clinical features and apoptosis by NOS inhibitor.
Leukemia. 13: 713-8, 1999.
[Journal]
217)  Mitsuya H, Erickson J.
Discovery and development of antiretroviral therapeutics for HIV infection.
Textbook of AIDS medicine, edited by Merigan, Bartlett, and Bolgnesi, Williams & Wilkins, Baltimore. 751-780, 1999.
[Journal]
218)  Sonoki T, Hata H, Kuribayashi N, Yoshida M, Harada N, Nagasaki A, Kimura T, Matsuno F, Mitsuya H, Matsuzaki H.
Expression of PRAD1/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects.
Br. J. Haematol. 104: 614-7, 1999.
[Journal]
219)  Uchida H, Kodama EN, Yoshimura K, Maeda Y, Kosalaraksa P, Maroun V, Qiu YL, Zemlicka J, Mitsuya H.
In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters.
Antimicrob. Agents Chemother. 43: 1487-90, 1999.
[Journal]
220)  Yoshimura K, Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J, Mitsuya H.
In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.
Antimicrob. Agents Chemother. 43: 2479-83, 1999.
[Journal]
221)  Okamoto M, Fujiwara M, Kodama E, Yamamoto O, Shigeta S, Mitsuya H, Konno K, Yokota T, Baba M.
Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative.
Antivir. Chem. Chemother. 10: 71-7, 1999.
[Journal]
222)  Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V, Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J, Masur H, Hayashi H, Erickson J, Mitsuya H.
JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.
Proc. Natl. Acad. Sci. U.S.A. 96: 8675-80, 1999.
[Journal]
223)  Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V, Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J, Masur H, Hayashi H, Erickson J, Mitsuya H.
JE-2147: a novel dipeptide protease inhibitor (PI) that potently inhibits multi-PI resistant HIV-1.
Proc. Natl. Acad. Sci. USA. 96: 8675-8680, 1999.
[Journal]
224)  Gao WY, Johns DG, Tanaka M, Mitsuya H.
Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Mol. Pharmacol. 55: 535-40, 1999.
[Journal]
225)  Maeda Y, Venzon DJ, Mitsuya H.
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
J. Infect. Dis. 177: 1207-13, 1998.
[Journal]
226)  Sonoki T, Nakazawa N, Hata H, Taniwaki M, Nagasaki A, Seto M, Yoshida M, Kuribayashi N, Kimura T, Harada N, Mitsuya H, Matsuzaki H.
Amplification and overexpression of the PRAD1/Cyclin D1 gene in a multiple myeloma cell line.
Int. J. Hematol. 68: 459-61, 1998.
[Journal]
227)  Roth JS, Ford H, Tanaka M, Mitsuya H, Kelley JA.
Determination of 2'-beta-fluoro-2',3'-dideoxyadenosine, an experimental anti-AIDS drug, in human plasma by high-performance liquid chromatography.
J. Chromatogr. B Biomed. Sci. Appl. 712: 199-210, 1998.
[Journal]
228)  Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H.
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
J. Infect. Dis. 177: 1506-13, 1998.
[Journal]
229)  Harada N, Hata H, Yoshida M, Soniki T, Nagasaki A, Kuribayashi N, Kimura T, Matsuzaki H, Mitsuya H.
Expression of Bcl-2 family of proteins in fresh myeloma cells.
Leukemia. 12: 1817-20, 1998.
[Journal]
230)  Mueller BU, Anderson BD, Farley MQ, Murphy R, Zuckerman J, Jarosinski P, Godwin K, McCully CL, Mitsuya H, Pizzo PA, Balis FM.
Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Antimicrob. Agents Chemother. 42: 1815-8, 1998.
[Journal]
231)  Gao WY, Zhou BS, Johns DG, Mitsuya H, Yen Y.
Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.
Biochem. Pharmacol. 56: 105-12, 1998.
[Journal]
232)  Rezende LF, Curr K, Ueno T, Mitsuya H, Prasad VR.
The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity.
J. Virol. 72: 2890-5, 1998.
[Journal]
233)  Ueno T, Mitsuya H.
Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay.
Biochemistry. 36: 1092-9, 1997.
[Journal]
234)  Brouwers P, Hendricks M, Lietzau JA, Pluda JM, Mitsuya H, Broder S, Yarchoan R.
Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens.
AIDS. 11: 59-66, 1997.
[Journal]
235)  Yusa K, Kavlick MF, Kosalaraksa P, Mitsuya H.
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
Antiviral Res. 36: 179-89, 1997.
[Journal]
236)  Uchida H, Maeda Y, Mitsuya H.
HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
Antiviral Res. 36: 107-13, 1997.
[Journal]
237)  Tanaka M, Srinivas RV, Ueno T, Kavlick MF, Hui FK, Fridland A, Driscoll JS, Mitsuya H.
In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.
Antimicrob. Agents Chemother. 41: 1313-8, 1997.
[Journal]
238)  Winter H, Maeda Y, Uchida H, Mitsuya H, Zemlicka J.
Phosphodiester amidates of unsaturated nucleoside analogues: synthesis and anti-HIV activity.
J. Med. Chem. 40: 2191-5, 1997.
[Journal]
239)  Humphrey RW, Ohagen A, Davis DA, Fukazawa T, Hayashi H, Höglund S, Mitsuya H, Yarchoan R.
Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
Antimicrob. Agents Chemother. 41: 1017-23, 1997.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 5/8/2014.